https://www.selleckchem.com/pr....oducts/ly3023414.htm
A greater proportion of the secondary prevention group met low-density lipoprotein targets compared to those without CVD (61.6% vs 40.9%, 0.01). In the secondary prevention group, beta-blockers were prescribed to only 20%, and 60% were prescribed antithrombotics, lipid-lowering medications, or agents targeting the renin-angiotensin-aldosterone system; 2% were prescribed medications from all 4 classes of cardioprotective medications. Primary and secondary CVD prevention recommendations for individuals with T2DM are not bei
Like
Comment
Share
